Literature DB >> 1552497

Novel 5-HT3 antagonists: indol-3-ylspiro(azabicycloalkane-3,5'(4'H)-oxazoles).

C J Swain1, R Baker, C Kneen, R Herbert, J Moseley, J Saunders, E M Seward, G I Stevenson, M Beer, J Stanton.   

Abstract

The synthesis and biochemical evaluation of a series of spirofused indole oxazoline 5-HT3 antagonists is described in which the oxazoline ring acts as a bioisosteric replacement for esters and amides. The effect of substitution about the indole ring has shown the steric limitations of the aromatic binding site. Incorporation of a variety of azabicyclic systems within the rigid spirofused framework has allowed the definition of a binding model which incorporates a number of known antagonists and agonists. In this model steric constraints limit substitution around the indole ring although there is some bulk tolerance at the 1- and 2-positions. The importance of constraining the basic nitrogen within an azabicyclic system is underlined by comparison with the monocyclic piperidine. The highest affinity was observed for those compounds in which the basic nitrogen occupies a bridgehead position, the most potent analogue in this group being the azabicyclic [3.3.1] system (pIC50 = 8.95), suggesting lipophilic interactions may play a role in increasing affinity. A suggested model for agonist binding is included in which the basic nitrogens are superimposed and the 5-hydroxyl group of 5-HT is superimposed on the H-bond-accepting atom of the heterocyclic linking group.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552497     DOI: 10.1021/jm00084a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  BMS-933043, a Selective α7 nAChR Partial Agonist for the Treatment of Cognitive Deficits Associated with Schizophrenia.

Authors:  Dalton King; Christiana Iwuagwu; Jim Cook; Ivar M McDonald; Robert Mate; F Christopher Zusi; Matthew D Hill; Haiquan Fang; Rulin Zhao; Bei Wang; Amy E Easton; Regina Miller; Debra Post-Munson; Ronald J Knox; Lizbeth Gallagher; Ryan Westphal; Thaddeus Molski; Jingsong Fan; Wendy Clarke; Yulia Benitex; Kimberley A Lentz; Rex Denton; Daniel Morgan; Robert Zaczek; Nicholas J Lodge; Linda J Bristow; John E Macor; Richard E Olson
Journal:  ACS Med Chem Lett       Date:  2017-02-08       Impact factor: 4.345

2.  5-HT3 receptor antagonism a potential therapeutic approach for the treatment of depression and other disorders.

Authors:  Shvetank Bhatt; Thangaraj Devadoss; Santhepete Nanjundaiah Manjula; Jayaraman Rajangam
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

3.  Functional group interactions of a 5-HT3R antagonist.

Authors:  Padmavati Venkataraman; Prasad Joshi; Srinivasan P Venkatachalan; Mani Muthalagi; Harish S Parihar; Karen S Kirschbaum; Marvin K Schulte
Journal:  BMC Biochem       Date:  2002-06-13       Impact factor: 4.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.